DE69638058D1 - Verpackungssysteme für humane rekombinante Adenoviren zur Gentherapie - Google Patents

Verpackungssysteme für humane rekombinante Adenoviren zur Gentherapie

Info

Publication number
DE69638058D1
DE69638058D1 DE69638058T DE69638058T DE69638058D1 DE 69638058 D1 DE69638058 D1 DE 69638058D1 DE 69638058 T DE69638058 T DE 69638058T DE 69638058 T DE69638058 T DE 69638058T DE 69638058 D1 DE69638058 D1 DE 69638058D1
Authority
DE
Germany
Prior art keywords
gene therapy
adenoviral
possibility
adenovirus
human recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69638058T
Other languages
English (en)
Inventor
Frits Jacobus Fallaux
Robert Cornelis Hoeben
Abraham Bout
Domenico Valerio
Der Eb Alex Jan Van
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Vaccines and Prevention BV
Original Assignee
Crucell Holand BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26139401&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69638058(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Crucell Holand BV filed Critical Crucell Holand BV
Application granted granted Critical
Publication of DE69638058D1 publication Critical patent/DE69638058D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C12N2710/10352—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
DE69638058T 1995-06-15 1996-06-14 Verpackungssysteme für humane rekombinante Adenoviren zur Gentherapie Expired - Lifetime DE69638058D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95201611 1995-06-15
EP95201728 1995-06-26

Publications (1)

Publication Number Publication Date
DE69638058D1 true DE69638058D1 (de) 2009-11-26

Family

ID=26139401

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69638058T Expired - Lifetime DE69638058D1 (de) 1995-06-15 1996-06-14 Verpackungssysteme für humane rekombinante Adenoviren zur Gentherapie
DE69633565T Expired - Lifetime DE69633565T3 (de) 1995-06-15 1996-06-14 Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69633565T Expired - Lifetime DE69633565T3 (de) 1995-06-15 1996-06-14 Verpackungssysteme für humane, menschliche adenoviren, zur verwendung in die gentherapie

Country Status (15)

Country Link
US (10) US5994128A (de)
EP (2) EP1445322B2 (de)
JP (2) JP4051416B2 (de)
KR (2) KR100449181B1 (de)
AT (2) ATE445705T1 (de)
AU (1) AU731767B2 (de)
CA (1) CA2222140C (de)
DE (2) DE69638058D1 (de)
DK (2) DK0833934T4 (de)
ES (2) ES2231813T5 (de)
HK (1) HK1064406A1 (de)
IL (3) IL122614A0 (de)
PT (2) PT1445322E (de)
SI (2) SI1445322T2 (de)
WO (1) WO1997000326A1 (de)

Families Citing this family (356)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0872552A1 (de) * 1997-04-15 1998-10-21 Leadd B.V. Genabgabe-Vehikel die das Apoptosis VP2 induzierendes Protein und/oder Apoptin exprimiert
NL9101680A (nl) 1991-10-04 1993-05-03 Tno Werkwijze voor het genetisch modificeren van beenmergcellen van primaten, alsmede daarbij bruikbare cellen die recombinante retrovirale vectoren produceren.
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US6080569A (en) * 1993-06-24 2000-06-27 Merck & Co., Inc. Adenovirus vectors generated from helper viruses and helper-dependent vectors
DK0668350T4 (da) * 1994-02-16 2009-02-23 Us Gov Health & Human Serv Melanomassocieret antigen, epitoper deraf samt vacciner mod melanom
US7252989B1 (en) * 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
AU711269B2 (en) 1994-08-16 1999-10-07 Crucell Holland B.V. Recombinant vectors derived from adenovirus for use in gene therapy
US5998205A (en) * 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
US6281010B1 (en) * 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
DE69638058D1 (de) 1995-06-15 2009-11-26 Crucell Holland Bv Verpackungssysteme für humane rekombinante Adenoviren zur Gentherapie
US6783980B2 (en) * 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6265212B1 (en) * 1995-06-15 2001-07-24 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US20020068049A1 (en) * 1998-09-10 2002-06-06 Henderson Daniel R. Tissue specific adenoviral vectors
EP0840797B1 (de) 1995-07-25 2014-09-03 Crucell Holland B.V. Verfahren und mittel zur gezielten freisetzung von genen
US6140103A (en) * 1995-12-01 2000-10-31 Introgene B.V. Regulated protein expression in stably transfected mammalian cells
US20040156861A1 (en) * 1996-07-11 2004-08-12 Figdor Carl Gustav Melanoma associated peptide analogues and vaccines against melanoma
US6110744A (en) * 1996-11-13 2000-08-29 Board Of Regents, The University Of Texas System Diminishing viral gene expression by promoter replacement
ES2215222T3 (es) 1996-12-05 2004-10-01 Crucell Holland B.V. Modificacion genetica de celulas cepa de repoblacion hematopoyeticas de primates.
US6403370B1 (en) 1997-02-10 2002-06-11 Genstar Therapeutics Corporation Oncolytic/immunogenic complementary-adenoviral vector system
CA2283253A1 (en) 1997-03-04 1998-09-11 Baxter International Inc. Adenovirus e1-complementing cell lines
US6696423B1 (en) 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
FR2774699B1 (fr) 1997-11-17 2003-10-03 Rhone Poulenc Rorer Sa Methode de reduction des evenements de recombinaison homologue
AU1536999A (en) * 1997-11-26 1999-06-15 Board Of Regents, The University Of Texas System Modified sv40 viral vectors
JP2001526900A (ja) 1997-12-23 2001-12-25 イントロヘーネ ベスローテン フェンノートシャップ 標的細胞の染色体ｄｎａへの外来遺伝子情報の組み込みに有用な、アデノ随伴ウイルスおよびアデノウイルスのキメラ組換えウイルス
AU2678999A (en) 1998-02-13 1999-08-30 Genetrace Systems, Inc. Use of ribozymes for functionating genes
US5981225A (en) * 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6670188B1 (en) * 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
EP0959136A1 (de) 1998-05-20 1999-11-24 Introgene B.V. Bei einem transporter von kationischen Aminosaüren zielgerichtete Darreichung
US6413776B1 (en) 1998-06-12 2002-07-02 Galapagos Geonomics N.V. High throughput screening of gene function using adenoviral libraries for functional genomics applications
US20040043489A1 (en) * 1998-07-08 2004-03-04 Menzo Havenga Gene delivery vectors provided with a tissue tropism for dendritic cells and methods of use
US20030017138A1 (en) * 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US6900049B2 (en) * 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
CA2348838A1 (en) * 1998-10-27 2000-05-04 Crucell Holland B.V. Improved aav vector production
IT1302403B1 (it) * 1998-11-06 2000-09-05 Angeletti P Ist Richerche Bio Cellule per la produzione di vettori adenovirali difettivi, metodoper la loro preparazione e loro uso.
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
IL133032A (en) * 1998-11-20 2007-06-03 Introgene Bv Adenoviral gene delivery vectors provided with a tissue tropism for smooth muscle cells and /or endothelial cells
EP1016726A1 (de) * 1998-12-30 2000-07-05 Introgene B.V. Gentherapie zur Förderung der Angiogenesis
US6869936B1 (en) 1999-03-04 2005-03-22 Crucell Holland B.V. Means and methods for fibroblast-like or macrophage-like cell transduction
WO2000052186A1 (en) * 1999-03-04 2000-09-08 Introgene B.V. Means and methods for fibroblast-like or macrophage-like cell transduction
US20050164386A1 (en) * 1999-04-15 2005-07-28 Uytdehaag Alphonsus G. Overexpression of enzymes involved in post-translational protein modifications in human cells
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US20060099685A1 (en) * 1999-04-15 2006-05-11 Yallop Christopher A Recombinant expression of factor VIII in human cells
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US20050170463A1 (en) * 1999-04-15 2005-08-04 Abraham Bout Recombinant protein production in permanent amniocytic cells that comprise nucleic acid encoding adenovirus E1A and E1B proteins
SI1533380T1 (sl) * 1999-04-15 2010-03-31 Crucell Holland Bv Proizvajanje rekombinantnega proteina v človeški celici ki obsega vsaj en protein E adenovirusa
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
WO2001007571A1 (en) * 1999-04-23 2001-02-01 Introgene B.V. Means and methods for nucleic acid transfer
PT1818408E (pt) 1999-05-17 2011-11-15 Crucell Holland Bv Adenovírus recombinante do serótipo ad11
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US20050232900A1 (en) * 1999-05-18 2005-10-20 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6913922B1 (en) * 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
JP2003530307A (ja) 1999-07-06 2003-10-14 メルク・アンド・カンパニー・インコーポレーテッド ｇａｇ遺伝子保有アデノウイルスＨＩＶワクチン
EP1067190A1 (de) * 1999-07-09 2001-01-10 Introgene B.V. Gentherapie zur Erhöhung und/oder Induktion der Angiogenese
EP1083229A1 (de) * 1999-09-10 2001-03-14 Introgene B.V. Veränderte adenovirale Vektoren für die Gentherapie
WO2001020014A1 (en) * 1999-09-10 2001-03-22 Crucell Holland B.V. Modified adenoviral vectors for use in gene therapy
EP1083228A1 (de) * 1999-09-10 2001-03-14 Introgene B.V. Veränderte adenovirale Vektoren für die Gentherapie
US6365394B1 (en) * 1999-09-29 2002-04-02 The Trustees Of The University Of Pennsylvania Cell lines and constructs useful in production of E1-deleted adenoviruses in absence of replication competent adenovirus
US7115391B1 (en) 1999-10-01 2006-10-03 Genovo, Inc. Production of recombinant AAV using adenovirus comprising AAV rep/cap genes
DE19955558C2 (de) * 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
US6558948B1 (en) 1999-11-23 2003-05-06 Stefan Kochanek Permanent amniocytic cell line, its production and use for the production of gene transfer vectors
US7192759B1 (en) * 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
US7521220B2 (en) * 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7527961B2 (en) 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
EP1238091A2 (de) * 1999-12-14 2002-09-11 Genovo, Incorporated Verfahren und zusammensetzungen zur herstellung von replicationsunfähigen adenovirus
EP1248653A2 (de) * 2000-01-07 2002-10-16 Stichting Klinische Farmacologie Groningen Gentherapie zur förderung von angiogenese sowie zur behandlung von herzinsuffienz
US7132277B1 (en) 2000-01-31 2006-11-07 Merck & Co., Inc. Helper dependent vector system for gene therapy
US6852528B2 (en) 2000-03-24 2005-02-08 Cell Genesys, Inc. Human and mouse uroplakin II gene transcriptional regulatory elements
US6680172B1 (en) 2000-05-16 2004-01-20 Regents Of The University Of Michigan Treatments and markers for cancers of the central nervous system
EP1157999A1 (de) * 2000-05-24 2001-11-28 Introgene B.V. Verfahren und Mitteln zur Verbesserung der Haut-Transplantation mittels Genabgabe-Vehikel mit Tropismus für primären Fibroblasten, sowie andere Verwendungsmöglichkeiten für diesen
KR20010064682A (ko) * 2000-07-01 2001-07-11 김재호 Ｅ1ｂ가 감쇠된 아데노바이러스를 이용한 ｃｄ／5－ｆｃ및 ｈｓｖ－1 ｔｋ／ｇｃｖ의 이중 자멸 유전자 시스템
US20020164333A1 (en) * 2000-07-10 2002-11-07 The Scripps Research Institute Bifunctional molecules and vectors complexed therewith for targeted gene delivery
AU2001278981A1 (en) * 2000-07-21 2002-02-05 Tom F Lue Prevention and treatment of sexual arousal disorders
US7223406B2 (en) * 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
US20080194022A1 (en) * 2000-08-03 2008-08-14 Clarke Michael F Isolation and use of solid tumor stem cells
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US6733993B2 (en) * 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
US20040101957A1 (en) * 2001-09-14 2004-05-27 Emini Emilio A. Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol.nef and modifications
WO2002024730A2 (en) * 2000-09-20 2002-03-28 Crucell Holland B.V. Transduction of dendritic cells using adenoviral vectors
DE60138403D1 (de) 2000-09-26 2009-05-28 Crucell Holland Bv Adenovirale vektoren für die übertragung von genen in zellen der skelettmuskulatur oder myoblasten
US6573092B1 (en) 2000-10-10 2003-06-03 Genvec, Inc. Method of preparing a eukaryotic viral vector
WO2002068627A2 (en) * 2001-02-23 2002-09-06 Novartis Ag Vector constucts
WO2002072790A2 (en) 2001-03-14 2002-09-19 Myriad Genetics, Inc Tsg101-gag interaction and use thereof
EP1256803A1 (de) * 2001-05-07 2002-11-13 Crucell Holland B.V. Verfahren zur Identifizierung von antiviralen Verbindungen
US6682929B2 (en) 2001-07-23 2004-01-27 Genvec, Inc. Adenovector complementing cells
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US20030119771A1 (en) * 2001-08-22 2003-06-26 Rompaey Luc Van Modulators of bone homeostasis identified in a high-throughput screen
CN1880457B (zh) 2001-10-11 2010-05-26 麦克公司 Ad6重组核酸
JP4475561B2 (ja) * 2001-10-11 2010-06-09 メルク・シャープ・エンド・ドーム・コーポレイション Ｃ型肝炎ウイルスワクチン
EA012340B1 (ru) 2001-10-29 2009-10-30 Круселл Холланд Б.В. Способ получения гликозилированной белковой молекулы, содержащей структуру lewis x, и/или сиалил-lewis x, и/или lacdinac
CN100547069C (zh) * 2001-12-07 2009-10-07 克鲁塞尔荷兰公司 病毒、病毒分离物和疫苗的生产
DE60226896D1 (de) * 2001-12-17 2008-07-10 Crucell Holland Bv Herstellung von f(ab')2 fragmenten in saügetierzelle
JP2005532036A (ja) 2002-01-09 2005-10-27 理化学研究所 癌プロフィール
EP1516055A4 (de) * 2002-01-24 2007-08-08 Scripps Research Inst Faserschaftmodifikationen für effizientes zielen
JP2005517942A (ja) * 2002-02-20 2005-06-16 メルク　エンド　カムパニー　インコーポレーテッド アデノ粒子濃度の測定方法
ES2871905T3 (es) 2002-03-01 2021-11-02 Immunomedics Inc Inmunoconjugado que comprende anticuerpos de RS7 humanizados
EP1492891B1 (de) * 2002-03-29 2008-02-20 Merck & Co., Inc. Verfahren zur virusproduktion
WO2003087348A1 (en) * 2002-04-08 2003-10-23 The Johns Hopkins University Packaging cell line for diphtheria toxin expressing non-replicating adenovirus
NZ534865A (en) * 2002-04-25 2008-07-31 Crucell Holland Bv Stable adenoviral vectors and methods for propagation thereof
ATE447037T1 (de) * 2002-04-25 2009-11-15 Crucell Holland Bv Mittel und verfahren zur herstellung von adenovirusvektoren
US20030219696A1 (en) * 2002-05-23 2003-11-27 Moreland Gerald W. Method and apparatus for preventing backflow in dental saliva evacuators
KR101143035B1 (ko) 2002-06-14 2012-05-08 이뮤노메딕스, 인코오포레이티드 단클론 항체 ｈＰＡＭ4
US7226755B1 (en) * 2002-09-25 2007-06-05 The Procter & Gamble Company HPTPbeta as a target in treatment of angiogenesis mediated disorders
US7507568B2 (en) * 2002-09-25 2009-03-24 The Proctor & Gamble Company Three dimensional coordinates of HPTPbeta
AU2003288273A1 (en) 2002-10-23 2004-05-13 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
US20080153083A1 (en) * 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
US20050221493A1 (en) * 2002-12-04 2005-10-06 Crucell Holland B.V. Recombinant virus production for the manufacturing of vaccines
WO2004055187A1 (en) 2002-12-17 2004-07-01 Crucell Holland B.V. Recombinant viral-based malaria vaccines
ATE354645T1 (de) * 2002-12-20 2007-03-15 Chromagenics Bv Mittel und methoden zur produktion eines proteins durch chromatin-öffner, die chromatin zugänglicher für transkriptionsfaktoren machen können
DE60331367D1 (de) 2002-12-30 2010-04-01 Angiotech Int Ag Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
US20040166091A1 (en) * 2003-02-24 2004-08-26 Genvec, Inc. Materials and methods for treating disorders of the ear
WO2004092396A2 (en) * 2003-04-15 2004-10-28 Novartis Ag Flap endonuclease 1 (fen1) regulatory sequences and uses thereof
WO2004092397A2 (en) * 2003-04-15 2004-10-28 Novartis Ag Tmprss2 regulatory sequences and uses thereof
ATE414144T1 (de) 2003-05-09 2008-11-15 Crucell Holland Bv Kulturen von e1-immortalisierten zellen und verfahren zu deren kultivierung zur erhöhung der produktausbeuten davon
AU2004240782B2 (en) * 2003-05-23 2011-04-21 Crucell Holland B.V. Production of recombinant IGM in per.C6 cells
US20050136035A1 (en) * 2003-06-03 2005-06-23 Derek Ko Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
WO2005017149A1 (en) * 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
EP2481814A3 (de) 2003-06-09 2012-10-10 The Regents of the University of Michigan Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Krebs
US7261882B2 (en) 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
US7026164B2 (en) * 2003-07-03 2006-04-11 Cell Genesys, Inc. Adenovirus packaging cell lines
US20050186178A1 (en) * 2003-08-28 2005-08-25 Ennist David L. Oncolytic adenoviral vectors encoding GM-CSF
NZ545501A (en) * 2003-10-02 2010-12-24 Crucell Holland Bv Packaging cells for recombinant adenovirus
US7482156B2 (en) * 2003-10-15 2009-01-27 Cell Genesys, Inc. Hepatocellular carcinoma specific promoter and uses thereof
EP1528101A1 (de) 2003-11-03 2005-05-04 ProBioGen AG Immortalisierte Vogel-Zelllinien für die Produktion von Viren
WO2005051432A1 (en) * 2003-11-14 2005-06-09 Genvec, Inc. Therapeutic regimen for treating cancer
EP1711518B1 (de) 2004-01-23 2009-11-18 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Impfstoffträger für schimpansen-adenovirus
CA2554779A1 (en) * 2004-02-03 2005-08-18 The Regents Of The University Of Michigan Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
DE602005015332D1 (de) * 2004-02-23 2009-08-20 Crucell Holland Bv Verfahren zur Reinigung von Viren
US7473418B2 (en) * 2004-03-25 2009-01-06 Cell Genesys, Inc. Pan cancer oncolytic vectors and methods of use thereof
AU2005243730B2 (en) 2004-04-12 2010-05-27 Genvec, Inc. Method of using adenoviral vectors to induce an immune response
JP2008505853A (ja) 2004-04-13 2008-02-28 クインテセンス バイオサイエンシーズ インコーポレーティッド 細胞傷害性薬剤としての非天然のリボヌクレアーゼ複合体
US7964196B2 (en) * 2004-05-25 2011-06-21 Chimeros, Inc. Self-assembling nanoparticle drug delivery system
US7858323B2 (en) 2004-06-09 2010-12-28 The Regents Of The University Of Michigan Phage microarray profiling of the humoral response to disease
US20060062764A1 (en) * 2004-08-25 2006-03-23 Seshidar-Reddy Police Fiber-modified adenoviral vectors for enhanced transduction of tumor cells
WO2006039045A2 (en) * 2004-09-01 2006-04-13 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenoviral vectors able to transduce apcs, potential use in immune response generation
DK2229956T3 (da) 2004-09-13 2013-07-29 Genzyme Corp Multimere konstruktioner
US7815623B2 (en) 2004-10-05 2010-10-19 Genzyme Corporation Stepped cannula
EP1799243B1 (de) 2004-10-06 2015-07-15 University Of Rochester Behandlung pulmonalen hochdrucks mit einem wirkstoff, der als gewebefaktorinhibitor fungiert
EP1805213B1 (de) * 2004-10-28 2015-11-18 University of Pittsburgh - Of the Commonwealth System of Higher Education Peripher verabreichte gentherapie mit glutaminsäure-decarboxylase gegen schmerzen aufgrund einer rückenmarksverletzung
US20060195935A1 (en) * 2004-11-08 2006-08-31 Chromagenics B.V. Selection of host cells expressing protein at high levels
US8039230B2 (en) * 2004-11-08 2011-10-18 Chromagenics B.V. Selection of host cells expressing protein at high levels
US8999667B2 (en) * 2004-11-08 2015-04-07 Chromagenics B.V. Selection of host cells expressing protein at high levels
AU2005300503B2 (en) 2004-11-08 2010-12-16 Chromagenics B.V. Selection of host cells expressing protein at high levels
DK1809750T3 (da) 2004-11-08 2012-06-25 Chromagenics Bv Selektion af værtsceller, der udtrykker protein ved høje niveauer
MX2007007145A (es) * 2004-12-13 2007-08-20 Canji Inc Lineas de celulas para produccion de adenovirus con replicacion defectuosa.
EP1856526A4 (de) 2005-01-20 2008-11-12 Univ Rochester Mit thioredoxin interagierendes protein (txnip) als regulator der gefässfunktion
AU2006212885A1 (en) * 2005-02-11 2006-08-17 Merck & Co., Inc. Adenovirus serotype 26 vectors, nucleic acid and viruses produced thereby
CN101155915B (zh) * 2005-04-11 2013-12-04 克鲁塞尔荷兰公司 利用超滤进行病毒纯化
US20060234347A1 (en) * 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
LT2816118T (lt) 2005-05-31 2018-12-10 The Regents Of The University Of Colorado, A Body Corporate Genų pristatymo būdai
EP1907858A4 (de) * 2005-06-13 2009-04-08 Univ Michigan Zusammensetzungen und verfahren zur behandlung und diagnose von krebs
WO2006135886A2 (en) * 2005-06-13 2006-12-21 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
EP1893636A2 (de) 2005-06-17 2008-03-05 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Hepatitis-c-virus-nukleinsäureimpfstoff
US7888102B2 (en) * 2005-07-22 2011-02-15 Crucell Holland B.V. Cell line for producing coronaviruses
US8450055B2 (en) * 2005-08-31 2013-05-28 The United States Of America As Represented By The Secretary Of The Navy Malaria antigen screening method
US9651543B2 (en) 2005-08-31 2017-05-16 The United States Of America As Represented By The Secretary Of The Navy Malaria antigen screening method
JP2009505680A (ja) 2005-08-31 2009-02-12 ジェンベク、インコーポレイティッド アデノウイルスベクターに基づくマラリアワクチン
US7718369B2 (en) 2005-09-12 2010-05-18 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US8652467B2 (en) * 2005-10-14 2014-02-18 The Regents Of The University Of Michigan Dek protein compositions and methods of using the same
US7794951B2 (en) * 2005-10-18 2010-09-14 University Of Massachusetts Medical School SREBP2gc transcription factors and uses thereof
RS54215B1 (en) 2005-10-31 2015-12-31 Oncomed Pharmaceuticals, Inc. COMPOSITIONS AND PROCEDURES FOR DIAGNOSIS AND TREATMENT OF CANCER
AU2006308847C1 (en) * 2005-10-31 2012-05-10 Oncomed Pharmaceuticals, Inc. Compositions and methods for treating and diagnosing cancer
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
EP1951297A2 (de) 2005-11-10 2008-08-06 GenVec, Inc. Adenoviraler vektorbasierter impfstoff für die maul- und klauen-seuche
WO2007070392A2 (en) * 2005-12-12 2007-06-21 Canji, Inc. Adenoviral expression vectors having an expression cassette in the e1 region and an inactivated e2b polymerase
AR059089A1 (es) 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
ES2697502T3 (es) 2006-02-09 2019-01-24 Genzyme Corp Administración intraventricular lenta
US20080019961A1 (en) * 2006-02-21 2008-01-24 Regents Of The University Of Michigan Hedgehog signaling pathway antagonist cancer treatment
EP1996705B1 (de) * 2006-03-20 2011-08-31 ChromaGenics B.V. Die expression verstärkende dna-fragmente, deren verwendung und verfahren zum finden dieser
BRPI0710645A2 (pt) 2006-04-07 2012-03-20 The Procter & Gamble Company Anticorpos que se ligam à proteína humana tirosina fosfatase beta (hptpbeta) e usos dos mesmos
WO2008108776A1 (en) * 2006-04-07 2008-09-12 Chimeros, Inc. Compositions and methods for treating b- cell malignancies
CA2655497A1 (en) 2006-06-23 2007-12-27 Myriad Genetics, Inc. Dpyd gene variants and use thereof
WO2007149594A2 (en) * 2006-06-23 2007-12-27 Quintessence Biosciences, Inc. Modified ribonucleases
US7589212B2 (en) * 2006-06-27 2009-09-15 Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US7795444B2 (en) * 2006-06-27 2010-09-14 Warner Chilcott Company Human protein tyrosine phosphatase inhibitors and methods of use
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US8846685B2 (en) 2006-06-27 2014-09-30 Aerpio Therapeutics Inc. Human protein tyrosine phosphatase inhibitors and methods of use
ES2650042T3 (es) 2006-07-14 2018-01-16 Patheon Holdings I B.V. Proceso mejorado para el cultivo de células
JP2009543868A (ja) 2006-07-17 2009-12-10 クインテセンス バイオサイエンシーズ インコーポレーティッド 癌治療に関する方法および組成物
US20080261216A1 (en) * 2006-09-08 2008-10-23 The Regents Of The University Of Michigan HERV Group II Viruses In Lymphoma And Cancer
WO2008086386A2 (en) * 2007-01-09 2008-07-17 Genvec, Inc. Adenoviral vector-based malaria vaccines
US11371194B2 (en) * 2007-01-19 2022-06-28 Brock Usa, Llc Base for turf system
WO2008092002A2 (en) * 2007-01-24 2008-07-31 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
WO2008112540A2 (en) * 2007-03-09 2008-09-18 Vectorlogics, Inc. Cells for adenovirus vector and protein production
AU2008236566A1 (en) * 2007-04-09 2008-10-16 Chimeros, Inc. Self-assembling nanoparticle drug delivery system
US20090324596A1 (en) 2008-06-30 2009-12-31 The Trustees Of Princeton University Methods of identifying and treating poor-prognosis cancers
US10745701B2 (en) 2007-06-28 2020-08-18 The Trustees Of Princeton University Methods of identifying and treating poor-prognosis cancers
EP2604701B1 (de) 2007-07-06 2015-11-04 The Regents Of The University Of Michigan Rezidivierende Genfusionen bei Prostatakrebs
WO2009026152A1 (en) 2007-08-16 2009-02-26 The Regents Of The University Of Michigan Metabolomic profiling of prostate cancer
DE102007041655A1 (de) 2007-09-03 2009-03-05 Medicyte Gmbh Vermehrung von primären Zellen und deren Verwendung
EP2205271B1 (de) * 2007-10-08 2014-05-21 Quintessence Biosciences, Inc. Zusammensetzungen und verfahren für therapien auf ribonukleasebasis
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
US8193151B2 (en) * 2008-04-25 2012-06-05 Northwestern University Methods for treating atrial or ventricular arrhythmias
US8518884B2 (en) 2008-04-25 2013-08-27 Northwestern University Methods for treating atrial or ventricular arrhythmias by administering a G-protein alpha inhibitor
AU2009272857B2 (en) * 2008-07-15 2015-06-18 Crucell Holland B.V. Scalable process for culturing PER.C6 cells and producing products therefrom
US8871515B2 (en) * 2008-09-17 2014-10-28 Isogenis, Inc. Construction of fully-deleted adenovirus-based gene delivery vectors and uses thereof
SG190568A1 (en) 2008-09-26 2013-06-28 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
BRPI0920743A2 (pt) 2008-10-01 2016-09-20 Quintessence Biosciences Inc ribonucleases terapeuticas
US20110184154A1 (en) * 2008-10-17 2011-07-28 Percivia Llc Cell broth clarification and host cell protein removal
MX2011004292A (es) * 2008-11-03 2011-05-31 Crucell Holland Bv Metodo para la produccion de vectores adenovirales.
WO2010081001A2 (en) 2009-01-09 2010-07-15 The Regents Of The University Of Michigan Recurrent gene fusions in cancer
US9096555B2 (en) 2009-01-12 2015-08-04 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome
PL2382474T3 (pl) 2009-01-20 2015-08-31 Transgene Sa Rozpuszczalny ICAM-1 jako biomarker do prognozowania odpowiedzi terapeutycznej
WO2010107991A2 (en) 2009-03-18 2010-09-23 Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Use of ixolaris, a tissue factor inhibitor, for the treatment and prevention of cancer
RU2542435C2 (ru) 2009-03-24 2015-02-20 Трансжене Са Биомаркер для мониторинга пациентов
WO2010120874A2 (en) 2009-04-14 2010-10-21 Chimeros, Inc. Chimeric therapeutics, compositions, and methods for using same
CN102395883B (zh) 2009-04-17 2015-12-02 特朗斯吉有限公司 用于监控患者的生物标志物
DK2421895T3 (en) 2009-04-23 2016-01-25 Crucell Holland Bv Recombinant human alpha 1-antitrypsin
EP3329932A1 (de) 2009-06-10 2018-06-06 New York University Immunologisches targeting von pathologischen tau-proteinen
US8883832B2 (en) 2009-07-06 2014-11-11 Aerpio Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
RU2519123C2 (ru) 2009-07-06 2014-06-10 Аэрпио Терапьютикс Инк. Соединения, композиции и способы предупреждения метастазов раковых клеток
EP2451935A2 (de) 2009-07-08 2012-05-16 Glycotope GmbH Perfusionsbioreaktor
RU2552292C2 (ru) 2009-07-10 2015-06-10 Трансжене Са Биомаркер для отбора пациентов и связанные с ним способы
SI2454364T1 (sl) * 2009-07-16 2014-08-29 Crucell Holland B.V. Izdelava polio virusa v visokih titrih za izdelavo cepiva
NZ598000A (en) 2009-08-07 2013-10-25 Transgene Sa Composition for treating hbv infection
US9605844B2 (en) * 2009-09-01 2017-03-28 Cree, Inc. Lighting device with heat dissipation elements
DK2488636T3 (da) * 2009-10-15 2014-06-23 Crucell Holland Bv Fremgangsmåde til oprensning af adenoviruspartikler fra kulturer med høj celledensitet
CN102575233B (zh) 2009-10-15 2014-07-16 克鲁塞尔荷兰公司 从高细胞密度培养物纯化腺病毒的方法
WO2011047316A1 (en) 2009-10-16 2011-04-21 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Nucleic acid sequences encoding expandable hiv mosaic proteins
CA2779632C (en) 2009-11-09 2019-08-20 Jason Gall Simian adenovirus and methods of use
WO2011057254A2 (en) 2009-11-09 2011-05-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Simian adenoviral vector-based vaccines
JP5960606B2 (ja) 2010-01-08 2016-08-02 プロフィブリックス ビーブイ 伸長α鎖を有するフィブリノーゲンが濃縮されたフィブリノーゲン調製物
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
CA2786835C (en) 2010-02-15 2021-08-31 Crucell Holland B.V. Method for the production of ad26 adenoviral vectors
EP2547362B1 (de) 2010-03-17 2021-08-25 Cornell University Unterbrochener impfstoff auf adenovirusbasis gegen drogenmissbrauch
WO2011116209A2 (en) * 2010-03-17 2011-09-22 The Regents Of The University Of Michigan Using phage epitopes to profile the immune response
JP2013527753A (ja) 2010-03-23 2013-07-04 イントレキソン コーポレーション 治療タンパク質を条件的に発現するベクター、該ベクターを含む宿主細胞およびそれらの使用
JP2013530929A (ja) 2010-04-01 2013-08-01 オンコメッド ファーマシューティカルズ インコーポレイテッド ｆｒｉｚｚｌｅｄ結合剤およびその使用
WO2012021730A2 (en) 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine
WO2012030512A1 (en) 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
EP2618838A1 (de) 2010-09-20 2013-07-31 Crucell Holland B.V. Therapeutische impfung gegen aktive tuberkulose
US9168292B2 (en) 2010-09-27 2015-10-27 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
DE102010041958A1 (de) 2010-10-04 2012-04-05 Medicyte Gmbh Geeignete Hepatozyten für in-vitro Genotoxitätstests
WO2012083297A2 (en) 2010-12-17 2012-06-21 Genvec, Inc. Adenoviral vectors with modified hexon regions
EP2654786B1 (de) 2010-12-20 2019-02-20 GenVec, Inc. Auf adenovirusvektor basierender impfstoff gegen denguefieber
WO2012092341A1 (en) 2010-12-28 2012-07-05 University Of Rochester Methods of modifying insulin signaling using biliverdin reductase (bvr) and bvr derived peptides
US9428565B2 (en) 2011-01-31 2016-08-30 The General Hospital Corporation Treatment and bioluminescent visualization using multimodal TRAIL molecules
JP6189754B2 (ja) 2011-03-04 2017-08-30 イントレキソン コーポレーション タンパク質を条件的に発現するベクター
WO2013001372A2 (en) 2011-06-30 2013-01-03 University Of Oslo Methods and compositions for inhibition of activation of regulatory t cells
EP2729173B1 (de) 2011-07-06 2016-06-15 Sykehuset Sorlandet HF Auf egfr zielende therapie
TWI623618B (zh) 2011-07-12 2018-05-11 傳斯堅公司 Ｈｂｖ聚合酶突變體
SI2753346T1 (sl) 2011-09-07 2020-09-30 Mount Sinai School Of Medicine Ceramidaza in diferenciacija celic
EP2747774A4 (de) 2011-09-09 2015-02-11 Biomed Realty L P Verfahren und zusammensetzungen zur kontrolle einer virusproteinassemblierung
WO2013045658A1 (en) 2011-09-29 2013-04-04 Transgene Sa Immunotherapy composition and regimen for treating hepatitis c virus infection
WO2013045668A2 (en) 2011-09-29 2013-04-04 Transgene Sa Immunotherapy composition and regimen for treating hepatitis c virus infection
US9233153B2 (en) 2011-10-05 2016-01-12 Genvec, Inc. Affenadenovirus (gorilla) or adenoviral vectors and methods of use
BR112014008284A2 (pt) 2011-10-05 2020-10-27 Genvec Inc. adenovirus (gorilla) simian ou vetores adenovirais e métodos de uso
WO2013052859A2 (en) 2011-10-05 2013-04-11 Genvec, Inc. Adenoviral vector-based respiratory syncytial virus (rsv) vaccine
BR112014008249B1 (pt) 2011-10-05 2022-03-15 Genvec Inc Adenovírus ou vetor adenoviral e composição com os mesmos
EP2780034A1 (de) 2011-11-14 2014-09-24 Crucell Holland B.V. Heterologe prime-boost-impfung mit auf masernviren basierten impfstoffen
KR101427200B1 (ko) 2011-11-24 2014-08-07 주식회사 바이로메드 아데노바이러스 생산 신규 세포주 및 그의 용도
US20150004144A1 (en) 2011-12-02 2015-01-01 The General Hospital Corporation Differentiation into brown adipocytes
CN104136613B (zh) 2011-12-08 2017-12-29 威洛克有限公司 带有毒性基因的载体、方法及其用途
US20150157700A1 (en) 2012-02-02 2015-06-11 GanVec, Inc. Adenoviral vector-based malaria vaccine
CN110917362A (zh) 2012-02-07 2020-03-27 全球生物疗法有限公司 核酸输送的区室化方法及其组合物和应用
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
HUE027839T2 (en) 2012-03-12 2016-11-28 Crucell Holland Bv Recombinant adenoviruses with altered terminals
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
CA2867950C (en) 2012-03-22 2023-02-21 Crucell Holland B.V. Vaccine against rsv
EP2855511B1 (de) 2012-05-29 2019-07-24 GenVec, Inc. Impfstoff gegen das herpes-simplex virus
EP2855669B1 (de) 2012-05-29 2018-10-10 GenVec, Inc. Modifizierte serotyp-28-adenovirusvektoren
WO2014009438A2 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterial antigen vaccine
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
AU2013298632B2 (en) 2012-08-03 2018-11-01 Sanofi Pasteur Production of infectious influenza viruses
US9605074B2 (en) 2012-08-30 2017-03-28 The General Hospital Corporation Multifunctional nanobodies for treating cancer
WO2014063155A1 (en) 2012-10-21 2014-04-24 University Of Rochester Thy1 (cd90) as a novel therapy to control adipose tissue accumulation
EP2911691B1 (de) 2012-10-23 2018-10-10 OncoMed Pharmaceuticals, Inc. Verfahren zur behandlung von neuroendokrinen tumoren mit wnt-pad-bindemitteln
US10106781B2 (en) 2012-11-16 2018-10-23 Beth Israel Deaconess Medical Center, Inc. Recombinant adenoviruses and use thereof
JP2016507493A (ja) 2012-12-21 2016-03-10 スィーケフス ソールラン ホーエフ 神経障害及び疼痛のｅｇｆｒ標的治療
EP2950885B1 (de) 2013-02-04 2018-11-21 Oncomed Pharmaceuticals, Inc. Verfahren und überwachung einer behandlung mit einem wnt-pfad-hemmer
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
KR101606910B1 (ko) 2013-03-29 2016-04-04 충북보건과학대학교 산학협력단 아데노바이러스 벡터 생산용 ａ５４９ 기반 세포주
US10640771B2 (en) 2013-04-17 2020-05-05 Genzyme Corporation Compositions and methods for treating and preventing macular degeneration
WO2014176259A1 (en) 2013-04-22 2014-10-30 Icahn School Of Medicine At Mount Sinai Mutations in pdgfrb and notch3 as causes of autosomal dominant infantile myofibromatosis
US10899800B2 (en) 2013-04-25 2021-01-26 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
US9988617B2 (en) 2013-05-21 2018-06-05 President And Fellows Of Harvard College Engineered heme-binding compositions and uses thereof
CA2914792C (en) 2013-06-17 2024-02-27 Crucell Holland B.V. Stabilized soluble pre-fusion rsv f polypeptides
ES2525768B1 (es) * 2013-06-24 2015-10-07 Curaxis, S.L. Procedimiento para la producción de proteínas recombinantes glicosiladas.
WO2015021443A1 (en) 2013-08-08 2015-02-12 Global Bio Therapeutics Usa, Inc. Clamp device for minimally invasive procedures and uses thereof
AP2016009154A0 (en) 2013-09-19 2016-04-30 Crucell Holland Bv Improved adenovirus formulations
EA201690684A1 (ru) 2013-09-30 2016-09-30 Круселл Холланд Б.В. Способ осветления выросшей клеточной массы неочищенной культуры клеток с высокой плотностью клеток
CN106103471B (zh) 2014-01-09 2020-01-07 特兰斯吉恩股份有限公司 异源寡聚分枝杆菌抗原的融合
CN111068072A (zh) 2014-02-06 2020-04-28 建新公司 用于治疗和预防黄斑变性的组合物及方法
EP2927685A1 (de) 2014-04-02 2015-10-07 Medicyte GmbH Geeignete Hepatozyten für In-vitro-Hepatitistests
CA2955877A1 (en) 2014-07-24 2016-01-28 Janssen Vaccines & Prevention B.V. Process for the purification of poliovirus from cell cultures
CA2957808A1 (en) 2014-09-07 2016-03-10 Selecta Biosciences, Inc. Methods and compositions for attenuating exon skipping anti-viral transfer vector immune responses
EP3194446B1 (de) 2014-09-18 2022-10-26 Cedars-Sinai Medical Center Zusammensetzungen und verfahren zur behandlung von fibrose
TWI710635B (zh) 2014-10-09 2020-11-21 美商珍維克公司 編碼人類無調同源物-1(hath1)之腺病毒載體
EP3421046A1 (de) 2014-11-04 2019-01-02 Janssen Vaccines & Prevention B.V. Therapeutische hpv16-impfstoffe
US10345259B2 (en) 2015-02-19 2019-07-09 Janssen Vaccines & Prevention B.V. Method for quantification of virus particles using capillary zone electrophoresis
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
ES2836432T3 (es) 2015-03-18 2021-06-25 Janssen Vaccines & Prevention Bv Ensayos para sistemas de expresión recombinante
CA2981841A1 (en) 2015-04-14 2016-10-20 Janssen Vaccines & Prevention B.V. Recombinant adenovirus expressing two transgenes with a bidirectional promoter
WO2016168601A1 (en) 2015-04-17 2016-10-20 Khalid Shah Agents, systems and methods for treating cancer
CN107708718B (zh) 2015-04-22 2022-01-11 西达-赛奈医疗中心 用于治疗2型糖尿病的肠内递送的苦味寡肽
JP6840718B2 (ja) 2015-07-07 2021-03-10 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 安定化された可溶性融合前ｒｓｖ ｆポリペプチド
EP3319633B1 (de) 2015-07-07 2020-11-11 Janssen Vaccines & Prevention B.V. Impfstoff gegen rsv
KR20180042295A (ko) 2015-08-20 2018-04-25 얀센 백신스 앤드 프리벤션 비.브이. 치료용 hpv18 백신
EA036412B1 (ru) 2015-10-06 2020-11-09 Янссен Вэксинс Энд Превеншн Б.В. Способ обеспечения защиты аденовируса от разрушения, вызванного взаимодействием с пластиком, и применение 2-гидроксипропил--циклодекстрина для защиты аденовируса
WO2017074517A1 (en) * 2015-10-30 2017-05-04 Seracare Life Sciences, Inc. Adenovirus control virus
US10377801B2 (en) 2015-11-04 2019-08-13 Northwestern University Amelioration of chronic kidney disease
US11273151B2 (en) 2015-11-04 2022-03-15 Icahn School Of Medicine At Mount Sinai Methods of treating tumors and cancer, and identifying candidate subjects for such treatment
JP7233928B2 (ja) 2016-04-05 2023-03-07 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｒｓｖに対するワクチン
BR112018070013A2 (pt) 2016-04-05 2019-02-05 Janssen Vaccines & Prevention Bv proteínas f do rsv pré-fusão solúveis estabilizadas
EP3448881B1 (de) 2016-04-26 2023-06-07 Icahn School of Medicine at Mount Sinai Behandlung von hippo-pfad-mutanten tumoren und verfahren zur identifizierung von probanden als kandidaten für die behandlung
AU2017259259B2 (en) 2016-05-02 2020-11-19 Bavarian Nordic A/S Therapeutic HPV vaccine combinations
WO2017191147A1 (en) 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
US11473105B2 (en) 2016-05-12 2022-10-18 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
CA3025441A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
WO2017220499A1 (en) 2016-06-20 2017-12-28 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
US11091795B2 (en) 2016-07-11 2021-08-17 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for diagnosing and treating arrhythmias
JP7229151B2 (ja) 2016-07-14 2023-02-27 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｈｐｖワクチン
WO2018064523A1 (en) 2016-09-30 2018-04-05 Genvec, Inc. Adenovectors for delivery of therapeutic genetic material into t cells
US20190328869A1 (en) 2016-10-10 2019-10-31 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
KR20190104194A (ko) 2017-01-07 2019-09-06 셀렉타 바이오사이언시즈, 인크. 합성 나노담체에 커플링된 면역억제제의 패턴화된 투여
WO2018140630A1 (en) 2017-01-25 2018-08-02 Northwestern University Autophagy inducers for treatment of cns conditions
CN110268061A (zh) 2017-02-09 2019-09-20 扬森疫苗与预防公司 用于表达异源基因的有效的短启动子
KR20190129857A (ko) 2017-02-17 2019-11-20 론자 리미티드 아데노-관련 바이러스 생산을 위한 포유동물 세포
WO2018194438A1 (ko) 2017-04-21 2018-10-25 (주)지뉴인텍 비복제 아데노 바이러스 생산 세포주 및 이의 제조방법
AU2018267971A1 (en) 2017-05-17 2019-11-07 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against RSV infection
JP2020533367A (ja) 2017-09-15 2020-11-19 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． Ｒｓｖに対する免疫の安全な誘導方法
AU2018347583A1 (en) 2017-10-13 2020-05-21 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector IgM responses
BR112020007698A2 (pt) 2017-10-31 2020-10-06 Janssen Vaccines & Prevention B.V. Sequência de ácido nucleico isolada, vetor, seu método de produção, célularecombinante, composição imunogênica, método para induzir uma resposta imune em um indivíduo, vacina e seu método de produção
AU2018359494A1 (en) 2017-10-31 2020-04-23 Janssen Vaccines & Prevention B.V. Adenovirus vectors and uses thereof
US11142551B2 (en) 2017-10-31 2021-10-12 Janssen Vaccines & Prevention B.V. Adenovirus and uses thereof
MA50502A (fr) 2017-10-31 2020-09-09 Janssen Vaccines & Prevention Bv Adénovirus et utilisations associées
EP3714043A4 (de) 2017-11-22 2021-08-11 The Regents of The University of Michigan Zusammensetzungen und verfahren zur behandlung von krebs
US11773142B2 (en) 2017-12-11 2023-10-03 Beth Israel Deaconess Medical Center, Inc. Recombinant adenoviruses and uses thereof
PE20210651A1 (es) 2018-01-23 2021-03-26 Janssen Vaccines And Prevention B V Vacunas contra virus de la gripe y usos de las mismas
AU2019231652A1 (en) 2018-03-06 2020-10-01 Precigen, Inc. Hepatitis B vaccines and uses of the same
TW202043256A (zh) 2019-01-10 2020-12-01 美商健生生物科技公司 前列腺新抗原及其用途
MX2021012991A (es) 2019-04-25 2021-12-10 Janssen Vaccines & Prevention Bv Antigenos de gripe recombinantes.
MX2021013163A (es) 2019-04-28 2022-02-21 Selecta Biosciences Inc Métodos para el tratamiento de sujetos con inmunidad preexistente a vectores de transferencia viral.
KR20220008816A (ko) 2019-05-15 2022-01-21 얀센 백신스 앤드 프리벤션 비.브이. 아데노바이러스 기반 백신을 사용한 호흡기 세포융합 바이러스 감염의 예방적 치료
JP2022532723A (ja) 2019-05-15 2022-07-19 ヤンセン ファッシンズ アンド プリベンション ベーフェー 季節性インフルエンザワクチン及びアデノウイルス系呼吸器合胞体ウイルスワクチンの共投与
EP3969046A1 (de) 2019-05-16 2022-03-23 Janssen Vaccines & Prevention B.V. Verfahren zur induzierung einer sicheren immunantwort gegen das poliovirus
MX2021014566A (es) 2019-05-28 2022-03-22 Selecta Biosciences Inc Métodos y composiciones para la respuesta inmune atenuada anti-vector de transferencia viral.
CA3152957A1 (en) 2019-09-05 2021-03-11 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
BR112022005268A2 (pt) 2019-10-03 2022-08-16 Janssen Vaccines & Prevention Bv Vetores adenovirais e usos dos mesmos
JP2023509571A (ja) 2019-11-18 2023-03-09 ヤンセン バイオテツク，インコーポレーテツド 変異型ｃａｌｒ及びｊａｋ２に基づくワクチン並びにこれらの使用
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
KR20220150353A (ko) 2020-03-05 2022-11-10 네오티엑스 테라퓨틱스 엘티디. 면역 세포를 사용하여 암을 치료하기 위한 방법 및 조성물
WO2021209897A1 (en) 2020-04-13 2021-10-21 Janssen Biotech, Inc. Psma and steap1 vaccines and their uses
WO2021215919A1 (en) 2020-04-21 2021-10-28 Polpharma Biologics Utrecht B.V. Humanized anti-human cd89 antibodies and uses thereof
US20230035403A1 (en) 2020-07-06 2023-02-02 Janssen Biotech, Inc. Method For Determining Responsiveness To Prostate Cancer Treatment
EP4175721A1 (de) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Prostata-neoantigene und ihre verwendungen
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
EP4178605A1 (de) 2020-07-13 2023-05-17 Transgene Behandlung von immundepression
US20220047645A1 (en) 2020-08-11 2022-02-17 Musculoskeletal Transplant Foundation Method for treating cardiac conditions with placenta-dervived compositions
EP4340855A1 (de) 2021-08-13 2024-03-27 Triovance Holding LLC Hautersatzzusammensetzung und verfahren zur herstellung und verwendung davon
WO2023064367A1 (en) 2021-10-12 2023-04-20 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
US20230357437A1 (en) 2022-03-09 2023-11-09 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
EP4338727A1 (de) 2022-09-14 2024-03-20 Roquette Freres Adenovirus-formulierungen

Family Cites Families (166)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US545522A (en) * 1895-09-03 Vehicle-wheel
US4497796A (en) 1980-03-26 1985-02-05 The Regents Of The University Of California Gene transfer in intact mammals
US4727028A (en) 1981-06-22 1988-02-23 Eli Lilly And Company Recombinant DNA cloning vectors and the eukaryotic and prokaryotic transformants thereof
US4405712A (en) 1981-07-01 1983-09-20 The United States Of America As Represented By The Department Of Health And Human Services LTR-Vectors
US4593002A (en) * 1982-01-11 1986-06-03 Salk Institute Biotechnology/Industrial Associates, Inc. Viruses with recombinant surface proteins
US4487829A (en) * 1982-03-23 1984-12-11 Massachusetts Institute Of Technology Production and use of monoclonal antibodies against adenoviruses
US4589881A (en) * 1982-08-04 1986-05-20 La Jolla Cancer Research Foundation Polypeptide
US4517686A (en) * 1982-08-04 1985-05-21 La Jolla Cancer Research Foundation Polypeptide
US4578079A (en) * 1982-08-04 1986-03-25 La Jolla Cancer Research Foundation Tetrapeptide
US4792525A (en) * 1982-08-04 1988-12-20 La Jolla Cancer Research Foundation Tetrapeptide
US5190931A (en) 1983-10-20 1993-03-02 The Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US5208149A (en) 1983-10-20 1993-05-04 The Research Foundation Of State University Of New York Nucleic acid constructs containing stable stem and loop structures
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4740463A (en) 1984-04-13 1988-04-26 Massachusetts Institute Of Technology Methods and artificial genes for antagonizing the function of an oncogene
FR2573436B1 (fr) 1984-11-20 1989-02-17 Pasteur Institut Adn recombinant comportant une sequence nucleotidique codant pour un polypeptide determine sous le controle d'un promoteur d'adenovirus, vecteurs contenant cet adn recombinant, cellules eucaryotes transformees par cet adn recombinant, produits d'excretion de ces cellules transformees et leurs applications, notamment a la constitution de vaccins
IL77081A (en) 1984-12-04 1999-10-28 Genetics Inst AND sequence encoding human erythropoietin, a process for its preparation and a pharmacological preparation of human erythropoietin
US4797368A (en) * 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5744133A (en) 1986-08-13 1998-04-28 Transgene S.A. Expression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventitive or curative treatment of the corresponding tumor
US6007806A (en) 1986-08-13 1999-12-28 Transgene S.A. Expression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventive or curative treatment of the corresponding tumor
US4835260A (en) 1987-03-20 1989-05-30 Genetics Institute, Inc. Erythropoietin composition
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US4956281A (en) * 1987-06-03 1990-09-11 Biogen, Inc. DNA sequences, recombinant DNA molecules and processes for producing lymphocyte function associated antigen-3
US5024939A (en) * 1987-07-09 1991-06-18 Genentech, Inc. Transient expression system for producing recombinant protein
US5378618A (en) * 1988-04-15 1995-01-03 E. I. Du Pont De Nemours And Company Vitro headful packaging system for cloning DNA fragments as large as 95kb
US5192539A (en) 1988-07-21 1993-03-09 Akzo N.V. Infectious bursal disease virus production in continuous cell lines
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5204445A (en) * 1988-10-03 1993-04-20 The Scripps Research Institute Peptides and antibodies that inhibit integrin-ligand binding
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5198346A (en) * 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en) * 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
GB8900483D0 (en) 1989-01-10 1989-03-08 Celltech Ltd Recombinant dna method
US5223394A (en) * 1989-04-10 1993-06-29 Biogen, Inc. Recombinant dna molecule comprising lymphocyte function-associated antigen 3 phosphatidylinositol linkage signal sequence
DE3923963A1 (de) 1989-07-20 1991-01-31 Behringwerke Ag Muteine des menschlichen erythropoetins, ihre herstellung und ihre verwendung
US5240846A (en) * 1989-08-22 1993-08-31 The Regents Of The University Of Michigan Gene therapy vector for cystic fibrosis
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5332567A (en) * 1989-08-24 1994-07-26 Immunomedics Detection and treatment of infections with immunoconjugates
US5436146A (en) * 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US5545522A (en) * 1989-09-22 1996-08-13 Van Gelder; Russell N. Process for amplifying a target polynucleotide sequence using a single primer-promoter complex
US5856298A (en) 1989-10-13 1999-01-05 Amgen Inc. Erythropoietin isoforms
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
WO1991018088A1 (en) * 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
US5349053A (en) * 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
US5246921A (en) * 1990-06-26 1993-09-21 The Wistar Institute Of Anatomy And Biology Method for treating leukemias
US6743623B2 (en) 1991-09-27 2004-06-01 Centre National De La Recherche Scientifique Viral recombinant vectors for expression in muscle cells
US5521291A (en) * 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5518913A (en) 1991-10-10 1996-05-21 National Research Council Of Canada High level recombinant protein production using conditional helper-free adenovirus vector
CA2053187A1 (en) 1991-10-10 1993-04-11 National Research Council Of Canada High level recombinant protein production using conditional helper-free adenovirus vector
US5384249A (en) 1991-12-17 1995-01-24 Kyowa Hakko Kogyo Co., Ltd. α2→3 sialyltransferase
JPH08501686A (ja) 1992-09-25 1996-02-27 ローン−プーラン・ロレ・ソシエテ・アノニム 中枢神経系、特に脳における細胞への外来遺伝子の転移のためのアデノウィルスベクター
EP0957172B1 (de) 1992-11-18 2005-10-19 Arch Development Corporation Adenovirus-gelenkter Gen-Transfer zum Herz-und glatten vaskulären Muskel
EP1024198A3 (de) * 1992-12-03 2002-05-29 Genzyme Corporation Pseudo-adenovirenvectors zur Gentherapie der Hämophilien
DE69220374T2 (de) 1992-12-23 1998-01-15 Campina Melkunie Bv Verfahren zur Gewinnung von Alpha-Lactalbumin und Beta-Lactoglobulin aus einem Molkeproteinprodukt
JPH09500782A (ja) * 1993-04-08 1997-01-28 ジェネティック セラピー，インコーポレイテッド 肺界面活性タンパク質をコード化するｄｎａを含むアデノウイルスベクター
DE4311651A1 (de) 1993-04-08 1994-10-13 Boehringer Ingelheim Int Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen
FR2704234B1 (fr) 1993-04-22 1995-07-21 Centre Nat Rech Scient Virus recombinants, preparation et utilisation en therapie genique.
FR2705361B1 (fr) * 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
US6133028A (en) * 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
DE69434486T2 (de) * 1993-06-24 2006-07-06 Advec Inc. Adenovirus vektoren für gentherapie
US5919676A (en) * 1993-06-24 1999-07-06 Advec, Inc. Adenoviral vector system comprising Cre-loxP recombination
KR100356615B1 (ko) * 1993-07-13 2003-04-03 아방티 파르마 소시에테 아노님 결함아데노바이러스벡터및유전자치료에서그의사용
FR2707664B1 (fr) 1993-07-13 1995-09-29 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
US5543328A (en) * 1993-08-13 1996-08-06 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
US5552311A (en) * 1993-09-14 1996-09-03 University Of Alabama At Birmingham Research Foundation Purine nucleoside phosphorylase gene therapy for human malignancy
US5534423A (en) * 1993-10-08 1996-07-09 Regents Of The University Of Michigan Methods of increasing rates of infection by directing motion of vectors
US6210939B1 (en) * 1993-10-25 2001-04-03 Canji, Inc. Recombinant adenoviral vector and methods of use
US5733782A (en) 1993-10-25 1998-03-31 Creative Biomolecules, Inc. Methods and compositions for high protein production from non-native DNA
US20010006629A1 (en) 1993-10-25 2001-07-05 Richard J. Gregory Recombinant adenoviral vector and methods of use
US5830851A (en) 1993-11-19 1998-11-03 Affymax Technologies N.V. Methods of administering peptides that bind to the erythropoietin receptor
US5773569A (en) 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
US5443953A (en) * 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates
WO1995016772A1 (en) 1993-12-14 1995-06-22 Cornell Research Foundation, Inc. Adenovirus gene expression system
US6057299A (en) 1994-01-13 2000-05-02 Calydon, Inc. Tissue-specific enhancer active in prostate
US5698443A (en) 1995-06-27 1997-12-16 Calydon, Inc. Tissue specific viral vectors
US5731172A (en) 1994-03-09 1998-03-24 Sumitomo Pharmaceuticals Company, Ltd. Recombinant adenovirus and process for producing the same
AU2194895A (en) 1994-03-25 1995-10-17 Uab Research Foundation, The Composition and methods for creating syngeneic recombinant virus-producing cells
US5789247A (en) 1994-04-01 1998-08-04 Ballay; Annick Expression in non-tumoral human lymphoblastoid lines with an integrative vector
US7252989B1 (en) * 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
EP0759300B1 (de) 1994-04-26 2002-02-27 Chugai Seiyaku Kabushiki Kaisha Verfahren für die herstellung schmelz-granulierte sucralfatzubereitung
US5851806A (en) * 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
EP1548118A2 (de) * 1994-06-10 2005-06-29 Genvec, Inc. Komplementäre adenovirale Vektor-Systeme und Zelllinien
FR2721943B1 (fr) 1994-06-29 1996-08-02 Rhone Poulenc Rorer Sa Adenovirus comprenant un gene codant pour une superoxyde dismutase
AU711269B2 (en) 1994-08-16 1999-10-07 Crucell Holland B.V. Recombinant vectors derived from adenovirus for use in gene therapy
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5846782A (en) * 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5552309A (en) * 1994-09-30 1996-09-03 Indiana University Foundation Use of polyols for improving the introduction of genetic material into cells
FR2725726B1 (fr) * 1994-10-17 1997-01-03 Centre Nat Rech Scient Vecteurs viraux et utilisation en therapie genique
EP0787200B1 (de) * 1994-10-28 2005-04-20 The Trustees Of The University Of Pennsylvania Rekombinanter adenovirus und methoden zu dessen verwendung
FR2726285B1 (fr) 1994-10-28 1996-11-29 Centre Nat Rech Scient Adenovirus depourvus de particules contaminantes viables, preparation et utilisation
US5856152A (en) * 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
US5872005A (en) 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
JPH10509879A (ja) * 1994-11-28 1998-09-29 ジェネティック セラピー， インコーポレイテッド 複製欠陥ベクターを用いる、組織特異的処置、診断方法、および組成物
CA2206683A1 (en) * 1994-12-12 1996-06-20 Genetic Therapy, Inc. Improved adenoviral vectors and producer cells
FR2727867B1 (fr) 1994-12-13 1997-01-31 Rhone Poulenc Rorer Sa Transfert de genes dans les motoneurones medullaires au moyen de vecteurs adenoviraux
GB9500659D0 (en) 1995-01-13 1995-03-08 Camco Drilling Group Ltd Improvements in or relating to rotary drill bits
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US5652224A (en) * 1995-02-24 1997-07-29 The Trustees Of The University Of Pennsylvania Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism
US6037453A (en) 1995-03-15 2000-03-14 Genentech, Inc. Immunoglobulin variants
US5707618A (en) * 1995-03-24 1998-01-13 Genzyme Corporation Adenovirus vectors for gene therapy
WO1996033280A1 (en) * 1995-04-17 1996-10-24 Board Of Regents, The University Of Texas System An adenovirus helper-virus system
JPH08303576A (ja) 1995-05-10 1996-11-19 Aisin Seiki Co Ltd 自動変速機の変速制御装置
US5767078A (en) 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
US6265212B1 (en) 1995-06-15 2001-07-24 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
DE69638058D1 (de) * 1995-06-15 2009-11-26 Crucell Holland Bv Verpackungssysteme für humane rekombinante Adenoviren zur Gentherapie
US6783980B2 (en) 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
FR2735789B1 (fr) * 1995-06-23 1997-07-25 Centre Nat Rech Scient Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant
US7001764B2 (en) 1995-06-27 2006-02-21 Cell Genesys, Inc. Compositions comprising tissue specific adenoviral vectors
US6676935B2 (en) 1995-06-27 2004-01-13 Cell Genesys, Inc. Tissue specific adenoviral vectors
FR2737222B1 (fr) * 1995-07-24 1997-10-17 Transgene Sa Nouveaux vecteurs viraux et lignee pour la therapie genique
FR2737501B1 (fr) * 1995-07-31 1997-10-24 Transgene Sa Nouveaux virus auxiliaires pour la preparation de vecteurs viraux recombinants
US5622699A (en) * 1995-09-11 1997-04-22 La Jolla Cancer Research Foundation Method of identifying molecules that home to a selected organ in vivo
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
JP3343357B2 (ja) 1995-11-13 2002-11-11 寳酒造株式会社 レトロウイルスによる標的細胞への遺伝子導入方法
US6140103A (en) * 1995-12-01 2000-10-31 Introgene B.V. Regulated protein expression in stably transfected mammalian cells
JP2001520511A (ja) * 1995-12-08 2001-10-30 ザ ユーナヴァーサティ オブ アラバマ アト バーミングハム リサーチ ファンデーション 向標的性アデノウイルス・ベクター
JP2001503962A (ja) * 1996-02-09 2001-03-27 ヘット ネーデルランツ カンケル インスティチュート 細胞のゲノム中に組込まれる付加核酸物質を細胞に付与するためのベクターおよび方法
US5835382A (en) 1996-04-26 1998-11-10 The Scripps Research Institute Small molecule mimetics of erythropoietin
CA2177085C (en) * 1996-04-26 2007-08-14 National Research Council Of Canada Adenovirus e1-complementing cell lines
US5877011A (en) * 1996-11-20 1999-03-02 Genzyme Corporation Chimeric adenoviral vectors
US5922315A (en) * 1997-01-24 1999-07-13 Genetic Therapy, Inc. Adenoviruses having altered hexon proteins
EP0856585A1 (de) * 1997-01-29 1998-08-05 Introgene B.V. Ein induzierbares Replications- und Expressionssystem
ATE296117T1 (de) * 1997-03-07 2005-06-15 Wistar Inst Verwendung von adenoviralen vektoren, die pdgf oder vegf exprimieren, zur heilung von gewebsdefekten und zur induzierung der hypervaskulität in säugergeweben
CA2221819A1 (en) 1997-03-27 1998-09-27 Thomas A. Gigliatti Insect expression vectors
US6100086A (en) 1997-04-14 2000-08-08 Genzyme Corporation Transgene expression systems
US5981275A (en) 1997-04-14 1999-11-09 Genzyme Corporation Transgene expression system for increased persistence
JP2002513290A (ja) 1997-05-08 2002-05-08 ジェネティック・セラピー・インコーポレテッド 修飾されたファイバー蛋白質を有するアデノウイルスによる遺伝子移入
US5849561A (en) * 1997-05-22 1998-12-15 Cornell Research Foundation, Inc. Method for the production of non-group C adenoviral vectors
US6287857B1 (en) * 1998-02-09 2001-09-11 Genzyme Corporation Nucleic acid delivery vehicles
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
WO1999047180A1 (en) 1998-03-20 1999-09-23 Genzyme Corporation Chimeric adenoviral vectors for targeted gene delivery
US6670188B1 (en) 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6413776B1 (en) * 1998-06-12 2002-07-02 Galapagos Geonomics N.V. High throughput screening of gene function using adenoviral libraries for functional genomics applications
AU4682999A (en) 1998-06-16 2000-01-05 Human Genome Sciences, Inc. 94 human secreted proteins
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
EP1020529B1 (de) 1998-11-20 2005-06-01 Crucell Holland B.V. Genverabreichende Vektoren mit Gewebetropismus für glatte Muskelzellen und/oder Endothelzellen
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
EP1016726A1 (de) 1998-12-30 2000-07-05 Introgene B.V. Gentherapie zur Förderung der Angiogenesis
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
WO2003048197A1 (en) 2001-12-07 2003-06-12 Crucell Holland B.V. Production and of viruses, viral isolates and vaccines
PT1818408E (pt) 1999-05-17 2011-11-15 Crucell Holland Bv Adenovírus recombinante do serótipo ad11
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US20050232900A1 (en) 1999-05-18 2005-10-20 Crucell Holland B.V. Serotype of adenovirus and uses thereof
EP1067188A1 (de) 1999-07-08 2001-01-10 Introgene B.V. Infektion mit chimärischen Adenoviren der Zellen die für den Adenoviren Serotyp 5 Coxsacki Adenoviren Rezeptor (CAR) negativ sind
US6558948B1 (en) 1999-11-23 2003-05-06 Stefan Kochanek Permanent amniocytic cell line, its production and use for the production of gene transfer vectors
US7527961B2 (en) 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
EP1103610A1 (de) 1999-11-26 2001-05-30 Introgene B.V. Impfstoffherstellung von immortalisierten Säugetierzellinien
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
AU2001257611A1 (en) 2000-04-28 2001-11-12 Avigen, Inc. Polynucleotides for use in recombinant adeno-associated virus virion production
EP1157999A1 (de) 2000-05-24 2001-11-28 Introgene B.V. Verfahren und Mitteln zur Verbesserung der Haut-Transplantation mittels Genabgabe-Vehikel mit Tropismus für primären Fibroblasten, sowie andere Verwendungsmöglichkeiten für diesen
US6844192B2 (en) 2001-06-29 2005-01-18 Wake Forest University Adenovirus E4 protein variants for virus production
US20030026783A1 (en) 2001-08-03 2003-02-06 Amine Abina Method of modulating neutralizing antibodies formation in mammals, and uses thereof in gene therapy, animal transgenesis and in functional inactivation of an endogenous proteins
EA012340B1 (ru) 2001-10-29 2009-10-30 Круселл Холланд Б.В. Способ получения гликозилированной белковой молекулы, содержащей структуру lewis x, и/или сиалил-lewis x, и/или lacdinac
CN100547069C (zh) 2001-12-07 2009-10-07 克鲁塞尔荷兰公司 病毒、病毒分离物和疫苗的生产
NZ534865A (en) 2002-04-25 2008-07-31 Crucell Holland Bv Stable adenoviral vectors and methods for propagation thereof
ATE447037T1 (de) 2002-04-25 2009-11-15 Crucell Holland Bv Mittel und verfahren zur herstellung von adenovirusvektoren
ES2442615T5 (es) 2002-07-18 2023-03-16 Merus Nv Producción recombinante de mezclas de anticuerpos
AU2003288273A1 (en) 2002-10-23 2004-05-13 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
WO2004055187A1 (en) 2002-12-17 2004-07-01 Crucell Holland B.V. Recombinant viral-based malaria vaccines
ATE414144T1 (de) 2003-05-09 2008-11-15 Crucell Holland Bv Kulturen von e1-immortalisierten zellen und verfahren zu deren kultivierung zur erhöhung der produktausbeuten davon
DE602005015332D1 (de) 2004-02-23 2009-08-20 Crucell Holland Bv Verfahren zur Reinigung von Viren
NZ583291A (en) 2004-10-14 2011-06-30 Glaxosmithkline Biolog Sa Malaria prime/boost vaccines using adenoviral vectors and adjuvated proteins
US20070010016A1 (en) 2005-03-11 2007-01-11 Mccelland Alan Gene transfer with adenoviruses having modified fiber proteins

Also Published As

Publication number Publication date
ATE445705T1 (de) 2009-10-15
DE69633565T2 (de) 2005-12-22
HK1064406A1 (en) 2005-01-28
DK1445322T3 (da) 2010-01-04
EP1445322B1 (de) 2009-10-14
JPH11507552A (ja) 1999-07-06
JP2006345872A (ja) 2006-12-28
CA2222140C (en) 2010-11-23
DE69633565T3 (de) 2013-01-17
IL122614A0 (en) 1998-08-16
DE69633565D1 (de) 2004-11-11
EP1445322A1 (de) 2004-08-11
IL160406A0 (en) 2004-07-25
US6306652B1 (en) 2001-10-23
ES2333425T3 (es) 2010-02-22
EP0833934A1 (de) 1998-04-08
ES2231813T5 (es) 2012-12-17
IL160406A (en) 2008-03-20
US6602706B1 (en) 2003-08-05
EP1445322B2 (de) 2012-06-06
AU731767B2 (en) 2001-04-05
ES2231813T3 (es) 2005-05-16
EP0833934B2 (de) 2012-08-15
US20090023196A1 (en) 2009-01-22
SI1445322T1 (sl) 2010-01-29
DK0833934T3 (da) 2005-02-07
US6238893B1 (en) 2001-05-29
KR100470180B1 (ko) 2005-02-04
DK1445322T4 (da) 2012-09-03
US8236293B2 (en) 2012-08-07
PT1445322E (pt) 2010-01-19
SI0833934T1 (en) 2005-02-28
US6395519B1 (en) 2002-05-28
ES2333425T5 (es) 2012-08-28
US20050221492A1 (en) 2005-10-06
US20020164802A1 (en) 2002-11-07
DK0833934T4 (da) 2012-11-19
PT833934E (pt) 2005-02-28
JP4051416B2 (ja) 2008-02-27
US20020151032A1 (en) 2002-10-17
US5994128A (en) 1999-11-30
KR100449181B1 (ko) 2005-01-24
SI1445322T2 (sl) 2012-10-30
AU6018296A (en) 1997-01-15
KR20040065317A (ko) 2004-07-21
WO1997000326A1 (en) 1997-01-03
EP0833934B1 (de) 2004-10-06
ATE278794T1 (de) 2004-10-15
CA2222140A1 (en) 1997-01-03
KR19990022941A (ko) 1999-03-25
US6033908A (en) 2000-03-07
SI0833934T2 (sl) 2013-04-30

Similar Documents

Publication Publication Date Title
DE69638058D1 (de) Verpackungssysteme für humane rekombinante Adenoviren zur Gentherapie
Chew et al. Innate and adaptive immune responses to herpes simplex virus
DE69806408D1 (de) Rekombinante impfstoffe die immunogene attenuierte rpos-positiv phentotyp bakterien enthalten
FI102382B1 (fi) Ilmentämisjärjestelmä ihmisen respiratory syncytial -viruksen glykoproteiinien immunogeenisia fragmentteja sisältäviä kimeerisiä glykoproteiineja varten
DE69430071D1 (de) Herstellung von rekombinanten proteinen in einem rinderadenovirus-expressionsvektorsystem
Liu et al. Promising cytomegalovirus-based vaccine vector induces robust CD8+ T-cell response
NO904538D0 (no) Kimaere glykoproteiner inneholdende immunogene segmenter av humant parainfluensavirus type 3.
AP2000001841A0 (en) Method for obtaining vaccines for preventing the pathgenic effects related to a retroviral infection.
Varon et al. Helicobacter pullorum cytolethal distending toxin targets vinculin and cortactin and triggers formation of lamellipodia in intestinal epithelial cells
ATE297750T1 (de) Verwendung von hsp70 protein
EP0319570A4 (en) Recombinant human cytomegalovirus containing foreign gene and use thereof
Strazic Geljic et al. Viral interactions with adaptor-protein complexes: a ubiquitous trait among viral species
DK0892054T3 (da) Clostridium perfringens-vaccine
ES2194012T3 (es) Epitopo p1a1 y p1a2 de la gpiii a de plaquetas, su preparacion y uso.
PT880594E (pt) Vector retroviral e sua utilizacao em terapia genica
WO2001044280A3 (en) Methods and compositions for the manufacture of replication incompetent adenovirus
Ossevoort et al. Characterization of an immuno ‘stealth’derivative of the herpes simplex virus thymidine-kinase gene
BR9912719A (pt) Processo para propagar um vìrus do herpes mutante, uso de uma linhagem de célula, linhagem de célula, vìrus, e, composição farmacêutica
DE69428984D1 (de) Stimulierung der immunantwort durch virales protein
Zou et al. α-Hemolysin-Aided Oligomerization of the Spike Protein RBD Resulted in Improved Immunogenicity and Neutralization Against SARS-CoV-2 Variants
Farzad et al. Feasibility of applying helper-dependent adenoviral vectors for cancer immunotherapy
ATE334207T1 (de) Zellzikluskontrollpunkt-spezifische gene
Cheroutre HIV vaccination: turning the spotlight on effector memory T cells as mucosal gatekeepers
Pei Characterization of Campylobacter jejuni conserved antigens and cell-binding factors for vaccine development.
V. Curlee et al. Design of Gene Therapy Clinical Trials in CF Patients

Legal Events

Date Code Title Description
8363 Opposition against the patent